Document Detail

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis.
MedLine Citation:
PMID:  21543733     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Due to a heightened risk of progressive multifocal leukoencephalopathy (PML) with increased natalizumab exposure, some physicians interrupt treatment of patients with multiple sclerosis (MS) despite a lack of data regarding the safety of treatment interruption, the rate and severity of MS disease activity return after treatment interruption, or alternative treatment strategies.
OBJECTIVES: To determine the effects of natalizumab treatment interruption on clinical and MRI measures of disease activity in relapsing patients with MS.
METHODS: Clinical relapses and gadolinium-enhanced (Gd+) lesions were analyzed over an 8-month period in patients from the AFFIRM, SENTINEL, and GLANCE studies of natalizumab, and their respective safety extension studies, following the voluntary suspension of natalizumab dosing that occurred in February 2005.
RESULTS: Relapses were analyzed in 1,866 patients, and Gd+ lesions were analyzed in 341 patients. Annualized relapse rates and Gd+ lesions both increased shortly after natalizumab interruption and peaked between 4 and 7 months. A consistent return of disease activity was observed regardless of overall natalizumab exposure, whether or not patients received alternative MS therapies, and in patients with highly active MS disease. A rebound of relapse or Gd+ lesion activity, beyond placebo-treated levels from the clinical studies, was not observed in any of the analyses conducted.
CONCLUSIONS: Following interruption of natalizumab treatment, MS disease activity returned in a pattern that was consistent with known pharmacokinetic and pharmacodynamic properties of natalizumab, and did not show evidence of rebound.
P W O'Connor; A Goodman; L Kappos; F D Lublin; D H Miller; C Polman; R A Rudick; W Aschenbach; N Lucas
Related Documents :
3770883 - Cardiac contusion in patients wearing seat belts.
20363273 - Association between matrix metalloproteinase 9 promoter polymorphisms and behçet's dis...
6893643 - Intraarticular substitution for anterior cruciate insufficiency. a clinical comparison ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2011-05-04
Journal Detail:
Title:  Neurology     Volume:  76     ISSN:  1526-632X     ISO Abbreviation:  Neurology     Publication Date:  2011 May 
Date Detail:
Created Date:  2011-05-31     Completed Date:  2011-07-26     Revised Date:  2011-12-30    
Medline Journal Info:
Nlm Unique ID:  0401060     Medline TA:  Neurology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1858-65     Citation Subset:  AIM; IM    
St. Michael's Hospital, Toronto, Ontario, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / adverse effects*
Antibodies, Monoclonal, Humanized
Clinical Trials as Topic
Multiple Sclerosis, Relapsing-Remitting / drug therapy*,  pathology*
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/natalizumab
Comment In:
Neurology. 2011 May 31;76(22):1854-5   [PMID:  21543735 ]
Neurology. 2011 Nov 22;77(21):1930; discussion 1930-1   [PMID:  22105950 ]
Expert Rev Neurother. 2011 Sep;11(9):1247-50   [PMID:  21864070 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Incident lacunes influence cognitive decline: the LADIS study.
Next Document:  Abbreviated report of the NIH/NINDS workshop on sudden unexpected death in epilepsy.